Literature DB >> 12740775

The hemi-Fontan operation.

Marshall L Jacobs1, Kamal K Pourmoghadam.   

Abstract

In hearts with a functional single ventricle, cavity volume and myocardial muscle mass increase as a consequence of the excessive volume load associated with parallel pulmonary and systemic circulations. The hemi-Fontan operation was conceived as a means of accomplishing early reduction of the volume work of the single ventricle, in anticipation of eventual completion of a modified Fontan procedure. The hemi-Fontan procedure includes association of the superior vena(e) cava(e) (SVC) with the branch pulmonary arteries, augmentation of the central pulmonary arteries, occlusion of the inflow of the SVC into the right atrium, and elimination of other sources of pulmonary blood flow. Because it is preparatory to an eventual completion Fontan procedure, concomitant procedures are conveniently performed in conjunction with the hemi-Fontan. These may include atrial septectomy, relief of aortic arch obstruction, proximal main pulmonary artery to ascending aortic anastomosis, repair or revision of anomalous pulmonary venous connection, atrioventricular valvuloplasty, or other procedures. Copyright 2003 Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2003        PMID: 12740775     DOI: 10.1053/pcsu.2003.50007

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu        ISSN: 1092-9126


  2 in total

1.  Preoperative assessment and follow-up of congenital abnormalities of the pulmonary arteries using CT and MRI.

Authors:  Sebastian Ley; Julia Zaporozhan; Raoul Arnold; Joachim Eichhorn; Jens-Peter Schenk; Herbert Ulmer; Karl-Friedrich Kreitner; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2006-06-24       Impact factor: 5.315

2.  Patient-specific computational fluid dynamic simulation of a bilateral bidirectional Glenn connection.

Authors:  Qi Sun; Dawei Wan; Jinfen Liu; Haifa Hong; Yingzheng Liu; Ming Zhu
Journal:  Med Biol Eng Comput       Date:  2008-08-26       Impact factor: 2.602

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.